Each will be eligible for its own PTE upon approval, creating a new layer of exclusivity that will extend the oligopolistic market structure in obesity treatment well into the 2030s
Zhang, The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation, Int
After undergoing extensive preclinical optimization and multiple successful clinical phases globally and in China, mazdutide received marketing approval in China in June 2025 under the brand name Xinermei, becoming the first domestically approved dual GLP-1/glucagon receptor agonist for weight management and glycemic control
Oxytocin treatment in children with Prader-Willi syndrome: a double-blinded, placebo-controlled, crossover study
#CiplaAt90 #CaringforLife Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
Tranexamic acid works by interrupting inflammatory signals that trigger excess melanin production
